



(51) International Patent Classification:

C07D 471/04 (2006.01) C07D 487/04 (2006.01)
 C07D 403/12 (2006.01) C07D 513/04 (2006.01)
 C07D 413/14 (2006.01) A61P 35/00 (2006.01)
 C07D 403/14 (2006.01) A61P 25/00 (2006.01)
 C07D 239/91 (2006.01) A61K 31/517 (2006.01)

(21) International Application Number:

PCT/US2015/035147

(22) International Filing Date:

10 June 2015 (10.06.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/011,977 13 June 2014 (13.06.2014) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: DU, Zhimin; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). EVARTS, Jerry; 4104 E. Garfield Street, Seattle, WA 98112 (US). KAPLAN, Joshua; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). KIM, Musong; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). NADUTHAMBI, Devan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PATEL, Leena; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PERR-EAULT, Stephane; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PHILLIPS, Barton, W.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PHILLIPS, Gary; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). STEVENS, Kirk, L.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TREIBERG, Jennifer; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). VAN VELDHUIZEN, Joshua; c/o Gilead Sciences, Inc., 333

Lakeside Drive, Foster City, CA 94404 (US). WATKINS, William, J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). YEUNG, Suet, Chung; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: MARQUART, Timothy, A. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS



(57) Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A¹, W¹, W², W³, R¹, R², and R³ are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*